Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving Average - Here's Why

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report)'s share price crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $16.70 and traded as low as $14.65. Seres Therapeutics shares last traded at $14.88, with a volume of 54,222 shares.Get Seres Therapeutics alerts:Wall Street Analysts Forecast GrowthA number of brokerages have recently issued reports on MCRB. Canaccord Genuity Group upped their price target on Seres Therapeutics from $14.00 to $22.00 and gave the company a "buy" rating in a report on Wednesday, September 24th. Weiss Ratings reissued a "sell (d)" rating on shares of Seres Therapeutics in a research report on Monday. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Reduce" and a consensus price target of $14.33.Read Our Latest Analysis on MCRBSeres Therapeutics Stock Up 3.0%The company has a market cap of $134.66 million, a P/E ratio of -4.17 and a beta of 0.18. The company has a fifty day moving average of $16.70 and a 200 day moving average of $16.03. Hedge Funds Weigh In On Seres TherapeuticsInstitutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE increased its holdings in Seres Therapeutics by 2,772.6% during the third quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company's stock valued at $103,000 after buying an additional 5,157 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Seres Therapeutics during the 2nd quarter valued at $249,000. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Seres Therapeutics in the 3rd quarter worth $557,000. Goldman Sachs Group Inc. increased its stake in shares of Seres Therapeutics by 40.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company's stock worth $52,000 after purchasing an additional 21,679 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in Seres Therapeutics in the 2nd quarter worth $1,016,000. Hedge funds and other institutional investors own 59.34% of the company's stock. About Seres Therapeutics (Get Free Report)Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company's approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted. Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.Featured ArticlesFive stocks we like better than Seres TherapeuticsThe Best $1 You'll Spend This Holiday SeasonHoliday surprise: $1 gets you everythingAmerica’s “most deplorable” Christmas saleMarket Panic: Trump Just Dropped a Bomb on Your StocksYour family's wealth expires in 2026?This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Seres Therapeutics Right Now?Before you consider Seres Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seres Therapeutics wasn't on the list.While Seres Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here